Skip to content

Left Ventricular End-Diastolic Pressure and Brain Natriuretic Peptide Guided Low-Dose Furosemide for Preventing Contrast-induced Nephropathy in the Percutaneous Coronary Intervention

Study of Low-Dose Furosemide for Preventing Contrast-induced Nephropathy in the Percutaneous Corona

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005250
Enrollment
Unknown
Registered
2014-09-24
Start date
2014-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced Nephropathy

Interventions

Control:hydration + furosemide
treatment:hydration + apply furosemide Individually

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.male or female, 18-75 years old; 2.Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.inability to obtain consent from participants; 2.primary percutaneous coronary intervention for ST-segment elevation myocardial infarction; 3. renal replacement therapy; 4.exposure to radiographic contrast media within the previous 2 days; 5.allergy to radiographic contrast media; 6.acute decompensated heart failure; 7.severe valvular heart disease; 8. mechanical aortic prosthesis; 9.left ventricular thrombus; 10.history of kidney or heart transplantation.

Design outcomes

Primary

MeasureTime frame
left ventricular end diastolic pressure;brain natriuretic peptide;creatinine;The incidence of contrast-induced nephropathy;

Secondary

MeasureTime frame
creatinine clearance rate;glomerular filtration rate;all-cause mortality;myocardial infarction;renal replacement therapy;Composite incidence of cardiac adverse events;

Countries

China

Contacts

Public ContactWei Cui
cuiwei@medmail.com.cn+86 15803210936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 2, 2026